Inotropes do not increase mortality in advanced heart failure

References

• FollathFYilmazMBDelgadoJFClinical presentation, management and outcomes in the acute heart failure global survey of standard treatment (ALARM-HF)Intensive Care Med20113761962621210078
   PubMed Web of Science ®Google Scholar
• RoseEAGelijnsACMoskowitzAJLong-term use of a left ventricular assist device for end-stage heart failureNew Engl J Med20013451435144311794191
   PubMed Web of Science ®Google Scholar
• YancyCWJessupMBozkurtBAmerican College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines2013 ACCF/AHA guideline for the management of heart failure: a report of the American College Of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20136216e147e23923747642
   PubMed Web of Science ®Google Scholar
• LindenfeldJAlbertNMBoehmerJPHFSA 2010 Comprehensive Heart Failure Practice GuidelineJ Card Fail201016e1e19420610207
   PubMed Web of Science ®Google Scholar
• McMurrayJJAdamopoulosSAnkerSDESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis And Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEur Heart J2012331787184722611136
   PubMed Web of Science ®Google Scholar
• JessupMBannerNBrozenaSOptimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates – 2006J Heart Lung Transplant2006251003102316962463
   PubMed Web of Science ®Google Scholar
• FeldmanDPamboukianSVTeutebergJJThe 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summaryJ Heart Lung Transplant20133215718723352391
   PubMed Web of Science ®Google Scholar
• CostanzoMRDipchandAStarlingRThe International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipientsJ Heart Lung Transplant20102991495620643330
   PubMed Web of Science ®Google Scholar
• SonnenblickEHFrishmanWHLeJemtelTHDobutamine: A new synthetic cardioactive sympathetic amineNew Engl J Med19793001722362214
   PubMed Web of Science ®Google Scholar
• BaimDSMcDowellAVChernilesJEvaluation of a new bipyridine inotropic agent – milrinone – in patients with severe congestive heart failureNew Engl J Med19833097487566888453
   PubMed Web of Science ®Google Scholar
• ValletBDupuisBChopinCDobutamine: mechanisms of action and use in acute cardiovascular pathologyAnn Cardiol Angeiol (Paris)199140397402 French1859148
   PubMedGoogle Scholar
• RuffoloRRJrThe pharmacology of dobutamineAm J Med Sci19872942442483310640
   PubMed Web of Science ®Google Scholar
• ColucciWSDennissARLeathermanGFIntracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibitionJ Clin Invest198881110311102832444
   PubMed Web of Science ®Google Scholar
• YoungRAWardAMilrinone. A preliminary review of its pharmacological properties and therapeutic useDrugs1988361581923053125
   PubMed Web of Science ®Google Scholar
• PiYZhangDKemnitzKRWangHWalkerJWProtein kinase c and a sites on troponin i regulate myofilament ca2+ sensitivity and atpase activity in the mouse myocardiumJ Physiol200355284585712923217
   PubMed Web of Science ®Google Scholar
• ColucciWSWrightRFJaskiBEFiferMABraunwaldEMilrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsivenessCirculation198673III175III1833510774
   PubMed Web of Science ®Google Scholar
• GivertzMMHareJMLohEGauthierDFColucciWSEffect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertensionJ Am Coll Cardiol199628177517808962566
   PubMed Web of Science ®Google Scholar
• PamboukianSVCarereRGWebbJGThe use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertensionJ Heart Lung Transplant19991836737110226902
   PubMed Web of Science ®Google Scholar
• BothaPParryGDarkJHMacgowanGAAcute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibitionJ Heart Lung Transplant20092867668219560695
   PubMed Web of Science ®Google Scholar
• AndersonJLHemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United StatesAm Heart J1991121195619642035427
   PubMed Web of Science ®Google Scholar
• KlockeRKMagerGKuxAHoppHWHilgerHHEffects of a twenty-four-hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial conditionAm Heart J1991121196519732035428
   PubMed Web of Science ®Google Scholar
• BiddleTLBenottiJRCreagerMAComparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathyAm J Cardiol198759134513503591689
   PubMed Web of Science ®Google Scholar
• MonradESBaimDSSmithHSLanoueASMilrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failureCirculation198673III168III1743510773
   PubMed Web of Science ®Google Scholar
• StevensonLWClinical use of inotropic therapy for heart failure: Looking backward or forward? Part I: inotropic infusions during hospitalizationCirculation200310836737212876135
   PubMed Web of Science ®Google Scholar
• LowesBDTsvetkovaTEichhornEJGilbertEMBristowMRMilrinone versus dobutamine in heart failure subjects treated chronically with carvedilolInt J Cardiol20018114114911744130
   PubMed Web of Science ®Google Scholar
• DavidSZaksJMArrhythmias associated with intermittent outpatient dobutamine infusionAngiology19863786913954157
   PubMed Web of Science ®Google Scholar
• BurgerAJHortonDPLeJemtelTEffect of nesiritide (b-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the precedent studyAm Heart J20021441102110812486437
   PubMed Web of Science ®Google Scholar
• ArandaJMJrSchofieldRSPaulyDFComparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trialAm Heart J200314532432912595851
   PubMed Web of Science ®Google Scholar
• TomaMStarlingRCInotropic therapy for end-stage heart failure patientsCurr Treat Options Cardiovasc Med20101240941920842563
   PubMedGoogle Scholar
• StevensonLWMassieBMFrancisGSOptimizing therapy for complex or refractory heart failure: a management algorithmAm Heart J1998135S293S3099630092
   PubMed Web of Science ®Google Scholar
• NohriaATsangSWFangJCClinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failureJ Am Coll Cardiol2003411797180412767667
   PubMed Web of Science ®Google Scholar
• LeierCVWebelJBushCAThe cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failureCirculation197756468472884803
   PubMed Web of Science ®Google Scholar
• StevensonLWClinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapyCirculation200310849249712885733
   PubMed Web of Science ®Google Scholar
• HershbergerRENaumanDWalkerTLDuttonDBurgessDCare processes and clinical outcomes of continuous outpatient support with inotropes (cosi) in patients with refractory endstage heart failureJ Card Fail2003918018712815567
   PubMed Web of Science ®Google Scholar
• UnverferthDVMagorienRDAltschuldRKolibashAJLewisRPLeierCVThe hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathyAm Heart J198310629346869193
   PubMed Web of Science ®Google Scholar
• CusickDAPfeiferPBQuiggRJEffects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failureAm J Cardiol199882106010659817482
   PubMed Web of Science ®Google Scholar
• CapomollaSFeboOOpasichCChronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcomeEur J Heart Fail2001360161011595609
   PubMed Web of Science ®Google Scholar
• SilverMAHortonDPGhaliJKElkayamUEffect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failureJ Am Coll Cardiol20023979880311869844
   PubMed Web of Science ®Google Scholar
• Levinoff RothSNMoeGIntermittent intravenous amrinone infusion: a potentially cost effective mode of treatment of patients with refractory heart failureCan J Cardiol199392312378508332
   PubMed Web of Science ®Google Scholar
• Marius-NunezALHeaneyLFernandezRNIntermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failureAm Heart J19961328058088831370
   PubMed Web of Science ®Google Scholar
• HatzizachariasAMakrisTKrespiPIntermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failureAm Heart J199913824124610426834
   PubMed Web of Science ®Google Scholar
• KrellMJKlineEMBatesERIntermittent, ambulatory dobutamine infusions in patients with severe congestive heart failureAm Heart J19861127877913766379
   PubMed Web of Science ®Google Scholar
• ApplefeldMMNewmanKASuttonFJOutpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patientsAm Heart J19871145895953630900
   PubMed Web of Science ®Google Scholar
• CesarioDClarkJMaiselABeneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary studyAm Heart J19981351211299453531
   PubMed Web of Science ®Google Scholar
• RoffmanDSApplefeldMMGroveWRIntermittent dobutamine hydrochloride infusions in outpatients with chronic congestive heart failureClin Pharm198541951993987220
   PubMedGoogle Scholar
• Lopez-CandalesALCarronCSchwartzJNeed for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropesClin Cardiol200427232814743852
   PubMed Web of Science ®Google Scholar
• ElisABentalTKimchiORavidMLishnerMIntermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled studyClin Pharmacol Ther1998636826859663183
   PubMed Web of Science ®Google Scholar
• ErlemeierHHKupperWBleifeldWIntermittent infusion of dobutamine in the therapy of severe congestive heart failure – long-term effects and lack of toleranceCardiovasc Drugs Ther199263913981520649
   PubMed Web of Science ®Google Scholar
• OlivaFLatiniRPolitiAIntermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trialAm Heart J199913824725310426835
   PubMed Web of Science ®Google Scholar
• HauptmanPJMikolajczakPGeorgeAChronic inotropic therapy in end-stage heart failureAm Heart J20061521096. e1e817161059
   PubMed Web of Science ®Google Scholar
• HarjaiKJMehraMRVenturaHOHome inotropic therapy in advanced heart failure: cost analysis and clinical outcomesChest1997112129813039367472
   PubMed Web of Science ®Google Scholar
• BrozenaSCTwomeyCGoldbergLRA prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at homeJ Heart Lung Transplant2004231082108615454175
   PubMed Web of Science ®Google Scholar
• CanverCCChandaJMilrinone for long-term pharmacologic support of the status 1 heart transplant candidatesAnn Thorac Surg2000691823182610892930
   PubMed Web of Science ®Google Scholar
• UpadyaSLeeFASaldarriagaCHome continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failureJ Heart Lung Transplant20042346647215063407
   PubMed Web of Science ®Google Scholar
• SindoneAPKeoghAMMacdonaldPSMcCoskerCJKaanAFContinuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacyAm Heart J19971348899009398101
   PubMed Web of Science ®Google Scholar
• MillerLWMerkleEJHerrmannVOutpatient dobutamine for end-stage congestive heart failureCrit Care Med199018S30S332293976
   PubMed Web of Science ®Google Scholar
• ElkayamUTasissaGBinanayCUse and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failureAm Heart J20071539810417174645
   PubMed Web of Science ®Google Scholar
• AbrahamWTAdamsKFFonarowGCADHERE Scientific Advisory Committee and InvestigatorsADHERE Study GroupIn-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (adhere)J Am Coll Cardiol200546576415992636
   PubMed Web of Science ®Google Scholar
• O’ConnorCMGattisWAUretskyBFContinuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (first)Am Heart J1999138788610385768
   PubMed Web of Science ®Google Scholar
• RossinenJHarjolaVPSiirila-WarisKThe use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational studyAcute Card Care20081020921318720087
   PubMedGoogle Scholar
• ThackraySEasthaughJFreemantleNClelandJGThe effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysisEur J Heart Fail2002451552912167393
   PubMed Web of Science ®Google Scholar
• AmsallemEKasparianCHaddourGBoisselJPNonyPPhosphodiesterase III inhibitors for heart failureCochrane Database Syst Rev20051CD00223015674893
   PubMed Web of Science ®Google Scholar
• GorodeskiEZChuECReeseJRShishehborMHHsichEStarlingRCPrognosis on chronic dobutamine or milrinone infusions for stage d heart failureCirc Heart Fail2009232032419808355
   PubMed Web of Science ®Google Scholar
• MehraMRVenturaHOKapoorCStapletonDDZimmermanDSmartFWSafety and clinical utility of long-term intravenous milrinone in advanced heart failureAm J Cardiol19978061649205021
   PubMed Web of Science ®Google Scholar
• UretskyBFJessupMKonstamMAMulticenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone multicenter trial groupCirculation1990827747802144216
   PubMed Web of Science ®Google Scholar
• CowleyAJSkeneAMTreatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone investigatorsBr Heart J1994722262307946771
   PubMedGoogle Scholar
• CohnJNGoldsteinSOGreenbergBHA dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone trial investigatorsNew Engl J Med1998339181018169854116
   PubMed Web of Science ®Google Scholar
• HamptonJRvan VeldhuisenDJKleberFXRandomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) InvestigatorsLancet19973499719779100622
   PubMed Web of Science ®Google Scholar
• PackerMCarverJRRodehefferRJEffect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research GroupNew Engl J Med1991325146814751944425
   PubMed Web of Science ®Google Scholar
• DrakosSGKanakakisJVNanasSIntermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failureJ Cardiovasc Pharmacol20095315716119188832
   PubMed Web of Science ®Google Scholar
• NanasJNTsagalouEPKanakakisJLong-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind studyChest20041251198120415078725
   PubMed Web of Science ®Google Scholar
• TsagalouEPAnastasiou-NanaMITerrovitisJVThe long-term survival benefit conferred by intermittent dobutamine infusions and oral amiodarone is greater in patients with idiopathic dilated cardiomyopathy than with ischemic heart diseaseInt J Cardiol200610824425016023232
   PubMed Web of Science ®Google Scholar
• CuffeMSCaliffRMAdamsKFJrShort-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trialJAMA20022871541154711911756
   PubMed Web of Science ®Google Scholar
• FelkerGMBenzaRLChandlerABHeart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF studyJ Am Coll Cardiol200341997100312651048
   PubMed Web of Science ®Google Scholar
• MetraMEichhornEAbrahamWTEffects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsEur Heart J2009303015302619700774
   PubMed Web of Science ®Google Scholar
• FeldmanAMOrenRMAbrahamWTLow-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trialAm Heart J200715486186917967591
   PubMed Web of Science ®Google Scholar
• ColucciWSSonnenblickEHAdamsKFEfficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The milrinone multicenter trials investigatorsJ Am Coll Cardiol199322113A118A
   Web of Science ®Google Scholar
• MassieBBourassaMDiBiancoRLong-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trialCirculation1985719639713886191
   PubMed Web of Science ®Google Scholar
• NaraharaKAOral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study GroupAm Heart J1991121147114791826806
   PubMed Web of Science ®Google Scholar
• van VeldhuisenDJMan in ‘t VeldAJDunselmanPHDouble-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)J Am Coll Cardiol199322156415737901256
   PubMed Web of Science ®Google Scholar
• DubourgODelormeGHardyABeauchetATarralABourdariasJPPlacebo-controlled trial of oral enoximone in end-stage congestive heart failure refractory to optimal treatmentInt J Cardiol199028Suppl 1S33S42 discussion S432145237
   PubMed Web of Science ®Google Scholar
• FeldmanAMBristowMRParmleyWWEffects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone study groupNew Engl J Med19933291491558515787
   PubMed Web of Science ®Google Scholar
• LikoffMJWeberKTAndrewsVAmrinone in the treatment of chronic cardiac failureJ Am Coll Cardiol19843128212906707381
   PubMed Web of Science ®Google Scholar
• BaruchLPatacsilPHameedAPinaILohEPharmacodynamic effects of milrinone with and without a bolus loading infusionAm Heart J200114126627311174341
   PubMed Web of Science ®Google Scholar
• Xamoterol in severe heart failure. The xamoterol in severe heart failure study groupLancet1990336161694945
   PubMed Web of Science ®Google Scholar
• DiBiancoRShabetaiRSilvermanBDLeierCVBenottiJROral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal studyJ Am Coll Cardiol198448558666386932
   PubMed Web of Science ®Google Scholar
• KhalifeKZannadFBrunotteFPlacebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluationAm J Cardiol19876075C79C
   Web of Science ®Google Scholar
• FrancisGSBartosJAAdatyaSInotropesJ Am Coll Cardiol2014
   Web of Science ®Google Scholar